Insmed (NASDAQ:INSM) Price Target Raised to $208.00

Insmed (NASDAQ:INSM) had its price objective upped by Stifel Nicolaus from $205.00 to $208.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on INSM. Royal Bank Of Canada raised their price objective on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Truist Financial set a $205.00 target price on Insmed in a research note on Monday, January 12th. Mizuho lowered their target price on Insmed from $211.00 to $204.00 and set an “outperform” rating on the stock in a report on Tuesday, February 24th. Bank of America raised their price target on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, TD Cowen set a $241.00 price target on Insmed in a report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $210.19.

Insmed Price Performance

Insmed stock opened at $147.60 on Tuesday. The firm has a market capitalization of $31.82 billion, a PE ratio of -23.03 and a beta of 1.13. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75. The firm’s 50-day simple moving average is $150.45 and its 200 day simple moving average is $165.98. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue was up 152.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.32) earnings per share. On average, equities research analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. This trade represents a 5.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the completion of the sale, the insider directly owned 41,754 shares of the company’s stock, valued at $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 189,651 shares of company stock worth $31,533,654 in the last three months. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in INSM. CoreCap Advisors LLC acquired a new position in Insmed in the fourth quarter valued at $27,000. Reflection Asset Management acquired a new stake in Insmed in the 4th quarter worth about $30,000. GraniteShares Advisors LLC acquired a new stake in Insmed in the 4th quarter worth about $30,000. CIBC Private Wealth Group LLC grew its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in shares of Insmed during the 4th quarter valued at about $32,000.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Positive Phase 3b ENCORE topline results for ARIKAYCE in MAC lung disease — a clear clinical win that strengthens the commercial and regulatory narrative for the lung‑disease franchise. Insmed reports positive topline results from phase 3b ENCORE study of Arikayce in patients with MAC lung disease
• Positive Sentiment: HC Wainwright raised its price target to $245 and maintained a Buy rating—one of the most bullish analyst moves, implying meaningful upside versus the current share price. Benzinga
• Positive Sentiment: Stifel increased its price target to $208, and Mizuho lifted its target to $206 (Outperform), providing additional analyst support behind the stock’s recovery narrative. Stifel Nicolaus Boosts Insmed (NASDAQ:INSM) Price Target to $208.00
• Positive Sentiment: Analysts at Leerink Partners and Bank of America signaled that the stock is likely to rise, reinforcing the post‑trial optimism among sell‑side firms. Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Leerink Partners Analyst Says
• Neutral Sentiment: Insmed hosted a shareholder/analyst call with a slide deck summarizing results and commercial strategy — useful for modeling uptake but not a headline catalyst by itself. Insmed Incorporated (INSM) Shareholder/Analyst Call – Slideshow
• Neutral Sentiment: CEO interviews and videos (coverage on MSN/other outlets) reiterate commercial opportunity and Japan market size, helpful color for adoption expectations. Insmed CEO on its Arikayce drug after shares surge on trial results
• Negative Sentiment: Wells Fargo trimmed its price target to $175, which introduces a more conservative valuation reference and may limit near‑term upside for some investors. Wells Fargo & Company Lowers Insmed (NASDAQ:INSM) Price Target to $175.00

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.